ABSTRACT It is widely regarded that the pharmaceutical sector is quite different from other manufactures for its character in inno-vation activities. This paper analyzed the nature of innovation activities by multinational companies (MNCs), which stand for foreign capital, focusing on two parameters named: size and scope of innovation through investigating patent data from 1985 to 2005. The paper reveals the role of the foreign capital and identifies their technology stratagem by developing a tool named Double- S Matrix. Research finding indicates that foreign capitals play an important role on overall national innovative competitiveness in this sector. Implications from this research can be used as reference to policy makers and business companies in China.
Cite this paper
nullL. Cao and X. Chen, "Technology Innovation Stratagem and Role Played by MNCs: Evidence from Chinese Pharmaceutical Sector," Journal of Service Science and Management, Vol. 1 No. 2, 2008, pp. 159-164. doi: 10.4236/jssm.2008.12017.
 Abernathy, W. J. and K. B. Clark (1985). "Innovation: Mapping the winds of creative destruction." Research Pol-icy 14(1): 3-22.
 Arundel A., I. Kabla. What percentage of innovations are patented? Empirical estimates for European firms. Re-search Policy 27(2),1998,pp: 127-141.
 Archibugi, D. and M. Pianta (1992). "Specialization and size of technological activities in industrial countries: The analysis of patent data." Research Policy 21(1): 79-93.
 Bogner, W. C. and H. Thomas (1996), 《Drug to Market: Creating Value and Advantage in the Pharmaceutical In-dustry》, New York: Pergamon
 Breschi, S., F. Lissoni, et al. (2003). "Knowledge-relatedness in firm technological diversification." Re-search Policy 32(1): 69-87.
 Castaldi, C., M. Milakovic, et al. Scale and technological factors in the diversification structure of business firms. Economics Letters 91(1),2006, pp: 117-121.
 Cantwell, J. and Vertova. Historical evolution of techno-logical diversification. Research Policy 33(3), 2004, pp: 511-529.
 Hara, T. (1997), ‘Industrial Technological Trajectories and Corporate Technology Traditions: the Development of Antibacterial Drugs in Japan’, Annals of the School of Business Administration, Kobe University, 41, 1-18
 McMillan, G. S., F. Narin, et al. An analysis of the critical role of public science in innovation: the case of biotech-nology. Research Policy 29(1),2000,pp: 1-8.
 Marx, L. and M. R. Smith. Introduction [A ]. in M. R. Smith and L. Marx ( eds) , Does Technological Determin-ism [C ]. Cambridge,MA: M IT Press, 1994. 9 - 15.
 Piscitello, L. (2000). "Relatedness and coherence in technological and product diversification of the world's largest firms." Structural Change and Economic Dynamics 11(3): 295-315.
 Swann, Peter and Prevezer, Martha（1996）. A Compari-son of the Dynamics of Industrial Clustering in Comput-ing and Biotechnology. Research Policy, 25(7):1139-1157.
 Tushman, M.L., Anderson, P.C., 1986. ‘Technological discontinuities and organizational environments’, Admin-istrative Science Quarterly, 31, 439–465
 Tushman, M., P. Anderson. 1986. Technological disconti-nuities and organizational environments. Admin. Sci. Quart.31 439-465.
 von Zedtwitz, M. and O. Gassmann, "Market versus tech-nology drive in R&D internationalization: four different patterns of managing research and development, Research Policy 31(4),2002, pp: 569-588.
 Zander, I. Technological diversification in the multina-tional corporation--historical evolution and future pros-pects. Research Policy 26(2): 209-227, 1997.
 Taylor, C. T., Silberston, Z.A. The Economic Impact of the Patent System: a Study of the British Experi-ence [M]. Cambridge University Press, Cambridge, 1973.
 Pavitt. Technology competencies in the world’s larg-est firms: complex and path-dependent, but not much variety [J]. Research Policy, 1997, 26 (2): 141-156.
 Chen xiangdong, Caolili, Comparative Study on in-digenous Innovation resource in Pharmaceutical Fields: An Entropy Measure over Patent Data in China[C]，international symposium on management of technology 2007:817-821